NEJM investigates allegations of research misconduct in a key study used to approve Amgen's drug Tavneos.
BLOOMBERG06/06, 05:01 AM
Related assets
Coming up for AMGN
Explore next
Latest AMGN news
Finnhub09/08, 09:50 PM
Jin1008/21, 10:49 PM
FirstSquawk08/05, 03:07 AM
Amgen raised its full-year adjusted EPS guidance to $22.30-$23.50 from the prior $21.70-$23.10.